Skip to main content

Advertisement

Log in

Pars plana vitrectomy with and without triamcinolone acetonide assistance in pseudophakic retinal detachment complicated with proliferative vitreoretinopathy

  • Clinical Investigation
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the anatomical and functional outcomes of pars plana vitrectomy (PPV) in pseudophakic retinal detachment (RD) complicated with proliferative vitreoretinopathy (PVR) without previous scleral buckling (SB) or vitrectomy, both with and without triamcinolone acetonide (TA) assistance.

Methods

In this retrospective, interventional, comparative case series, 72 pseudophakic eyes with RD with PVR grade C1 or greater underwent PPV either with (group 1, n = 40) or without (group 2, n = 32) TA assistance. Eyes with a minimum of 6 months of follow-up were evaluated. Main outcome measures were reattachment, redetachment, complication rate, and changes in visual acuity (VA).

Results

The mean follow-up period was 14.57 ± 8.55 months. Single-surgery and final reattachment rates were 87.50% and 95% in group 1, and 78.12 % and 96.87% in group 2, (P = 0.349, P = 1.000). Redetachment rates were 12.50% in group 1 and 21.87% group 2 (P = 0.349). In both groups the mean VA increased significantly in postoperative week 1 and in all control visits (P< 0.001) with no difference in complication rate (P > 0.05).

Conclusions

In this study PPV with TA assistance resulted in a lower, albeit statistically insignificant, redetachment rate in the treatment of RD complicated with PVR compared to PPV without TA assistance in eyes without previous SB or PPV. Visual acuity improved in 72% of eyes in both groups. Intraoperative and postoperative complication rates were also similar.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Abrams GW, Azen SP, McCuen BW 2nd, Flynn HW Jr, Lai MY, Ryan SJ. Vitrectomy with silicone oil or long-acting gas in eyes with severe proliferative vitreoretinopathy: results of additional and long-term follow-up. Silicone Study report 11. Arch Ophthalmol 1997;115:335–344; comment, Arch Ophthalmol 1997;115:407–408.

    CAS  PubMed  Google Scholar 

  2. Peyman GA, Cheema R, Conway MD, Fang T. Triamcinolone acetonide as an aid to visualization of the vitreous and the posterior hyaloid during pars plana vitrectomy. Retina 2000;20:554–555.

    CAS  PubMed  Google Scholar 

  3. Sakamoto T, Miyazaki M, Hisatomi T, et al. Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood-ocular barrier breakdown. Graefes Arch Clin Exp Ophthalmol 2002;240:423–429.

    Article  PubMed  Google Scholar 

  4. Furino C, Micelli Ferrari T, Boscia F, Cardascia N, Recchimurzo N, Sborgia C. Triamcinolone-assisted pars plana vitrectomy for proliferative vitreoretinopathy. Retina 2003;23:771–776.

    Article  PubMed  Google Scholar 

  5. Ueno A, Enaida H, Hata Y, et al. Long-term clinical outcomes and therapeutic benefits of triamcinolone-assisted pars plana vitrec tomy for proliferative vitreoretinopathy: a case study. Eur J Ophthalmol 2007;17:392–398.

    CAS  PubMed  Google Scholar 

  6. Enaida H, Hata Y, Ueno A, et al. Possible benefits of triamcinolone-assisted pars plana vitrectomy for retinal diseases. Retina 2003;23:764–770.

    Article  PubMed  Google Scholar 

  7. The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology 1983;90:121–125.

  8. Silicone Study Group. Silicone study report 4. Postoperative intraocular pressure abnormalities in the Silicone Study: results of a randomized clinical trial. Ophthalmology 1993;100:1629–1635.

    Google Scholar 

  9. Thompson JT. Proliferative vitreoretinopathy. In: Ryan SJ, editor. Retina, 4th ed. Philadelphia: Mosby; 2006. p. 2301.

    Google Scholar 

  10. Vitrectomy with silicone oil or perfluoropropane gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Silicone study report 2. Arch Ophthalmol 1992;110: 780–792.

  11. Lewis H, Aaberg TM, Abrams GW. Causes of failure after initial vitreoretinal surgery for severe proliferative vitreoretinopathy. Am J Ophthalmol 1991;111:8–14.

    CAS  PubMed  Google Scholar 

  12. Proliferative vitreoretinopathy. The Silicone Study Group. Am J Ophthalmol 1985;99:593–595.

    Google Scholar 

  13. Tseng W, Cortez RT, Ramirez G, Stinnett S, Jaffe GJ. Prevalence and risk factors for proliferative vitreoretinopathy in eyes with rhegmatogenous retinal detachment but no previous vitreoretinal surgery. Am J Ophthalmol 2004;137:1105–1115.

    Article  PubMed  Google Scholar 

  14. Sonoda KH, Sakamoto T, Enaida H, et al. Residual vitreous cortex after surgical posterior vitreous separation visualized by intravitreous triamcinolone acetonide. Ophthalmology 2004;111:226–230.

    Article  PubMed  Google Scholar 

  15. Yamakiri K, Sakamoto T, Noda Y, et al. Reduced incidence of intraoperative complications in a multicenter controlled clinical trial of triamcinolone in vitrectomy. Ophthalmology 2007;114: 289–296.

    Article  PubMed  Google Scholar 

  16. Yamakiri K, Sakamoto T, Noda Y, et al. One-year results of a multicenter controlled clinical trial of triamcinolone in pars plana vitrectomy. Graefes Arch Clin Exp Ophthalmol 2008;246:959–966.

    Article  CAS  PubMed  Google Scholar 

  17. Dyer D, Callanan D, Bochow T, et al. Clinical evaluation of the safety and efficacy of preservative-free triamcinolone (Triesence [triamcinolone acetonide injectable suspension] 40 mg/ml) for visualization during pars plana vitrectomy. Retina 2009;29:38–45.

    Article  PubMed  Google Scholar 

  18. Mańkowska A, Rejdak R, Oleszczuk A, et al. Decrease of the postoperative inflammatory reaction during pars plana vitrectomy (PPV) after administration of triamcinolone acetonide. Klin Oczna 2008;110:151–154.

    PubMed  Google Scholar 

  19. Diabetic Retinopathy Clinical Research Network (DRCR.net), Beck RW, Edwards AR, Aiello LP, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009;127:245–251.

    Article  PubMed  Google Scholar 

  20. Enaida H, Sakamoto T, Ueno A, et al. Submacular deposition of triamcinolone acetonide after triamcinolone-assisted vitrectomy. Am J Ophthalmol 2003;135:243–246.

    Article  PubMed  Google Scholar 

  21. Baath J, Ells AL, Crichton A, Kherani A, Williams RG. Safety profile of intravitreal triamcinolone acetonide. J Ocul Pharmacol Ther 2007;23:304–310.

    Article  CAS  PubMed  Google Scholar 

  22. McCuen BW 2nd, Bessler M, Tano Y, Chandler D, Machemer R. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol 1981;91:785–788.

    CAS  PubMed  Google Scholar 

  23. Hida T, Chandler D, Arena JE, Machemer R. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol 1986;101:190–195.

    CAS  PubMed  Google Scholar 

  24. Sakamoto T, Enaida H, Kubota T, et al. Incidence of acute endophthalmitis after triamcinolone-assisted pars plana vitrectomy. Am J Ophthalmol 2004;138:137–138.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Nur Acar.

About this article

Cite this article

Acar, N., Kapran, Z., Altan, T. et al. Pars plana vitrectomy with and without triamcinolone acetonide assistance in pseudophakic retinal detachment complicated with proliferative vitreoretinopathy. Jpn J Ophthalmol 54, 331–337 (2010). https://doi.org/10.1007/s10384-010-0807-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-010-0807-z

Keywords

Navigation